CorMedix (CRMD)
(Delayed Data from NSDQ)
$8.90 USD
+0.61 (7.36%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $8.90 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for CorMedix Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 49 | 31 | 29 | 27 | 21 |
Income After Depreciation & Amortization | -49 | -31 | -29 | -27 | -21 |
Non-Operating Income | 3 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 1 |
Pretax Income | -46 | -30 | -29 | -27 | -21 |
Income Taxes | 0 | -1 | -1 | -5 | -5 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -46 | -30 | -28 | -22 | -16 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -46 | -30 | -28 | -22 | -16 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -49 | -30 | -29 | -27 | -21 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -49 | -31 | -29 | -27 | -21 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 50.90 | 40.27 | 37.67 | 28.56 | 24.15 |
Diluted EPS Before Non-Recurring Items | -0.91 | -0.74 | -0.75 | -0.77 | -0.89 |
Diluted Net EPS (GAAP) | -0.91 | -0.74 | -0.75 | -0.77 | -1.80 |
Fiscal Year end for CorMedix Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 0.81 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.51 | 0.82 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.30 | -0.82 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 15.60 | 15.89 | 15.67 | 10.46 | 11.80 |
Income After SG&A, R&D, and Dept/Amort Expenses | -15.30 | -16.71 | -15.67 | -10.46 | -11.80 |
Non-Operating Income | 1.16 | 0.85 | 0.92 | 0.74 | 0.54 |
Interest Expense | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Pretax Income | -14.15 | -15.86 | -14.75 | -9.74 | -11.27 |
Income Taxes | 0.00 | -1.39 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -14.15 | -14.47 | -14.75 | -9.74 | -11.27 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -14.15 | -14.47 | -14.75 | -9.74 | -11.27 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 57.62 | 57.50 | 57.39 | 56.55 | 45.37 |
Diluted EPS Before Non-Recurring Items | -0.25 | -0.25 | -0.26 | -0.17 | -0.25 |
Diluted Net EPS (GAAP) | -0.25 | -0.25 | -0.25 | -0.17 | -0.25 |